562 related articles for article (PubMed ID: 24577748)
1. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
[TBL] [Abstract][Full Text] [Related]
2. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
[TBL] [Abstract][Full Text] [Related]
6. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
8. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
9. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
Johnson DB; Pectasides E; Feld E; Ye F; Zhao S; Johnpulle R; Merritt R; McDermott DF; Puzanov I; Lawrence D; Sosman JA; Buchbinder E; Sullivan RJ
J Immunother; 2017 Jan; 40(1):31-35. PubMed ID: 27846054
[TBL] [Abstract][Full Text] [Related]
10. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L
BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025
[TBL] [Abstract][Full Text] [Related]
11. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
14. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
15. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
16. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
17. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
19. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
[TBL] [Abstract][Full Text] [Related]
20. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]